Table of Content

1. Introduction and Market Definition
1.1 What are Immuno-Oncology Diagnostics?
1.2 Immuno-oncology - the looming cure
1.2.1 Immuno-oncology Diagnostics Takes a Leading Role
1.3 Market Definition
1.3.1 Market Size
1.3.2 Currency
1.3.3 Years
1.4 Methodology
1.4.1 Authors
1.4.2 Sources
1.5 U.S. Medical Market and laboratory Testing - Perspective
1.5.1 U.S. Medicare Expenditures for Laboratory Testing

2. Immunotherapy - Guide to Immune Technologies
2.0 The Immune System
2.0.1 Innate immune system
2.0.1.1 Surface barriers
2.0.1.2 Inflammation
2.0.1.3 Complement system
2.0.1.4 Cellular barriers
2.0.1.5 Natural killer cells
2.0.2 Adaptive immune system
2.0.2.1 Lymphocytes
2.0.2.2 Killer T cells
2.0.2.3 Helper T cells
2.0.2.4 Gamma delta T cells
2.0.2.5 B lymphocytes and antibodies
2.0.3 Tumor immunology - the immune surveillance system
2.1 Immuno Oncology Diagnostics
2.1.1 Checkpoint Assays
2.1.1.1 Outlook for Checkpoint Assays
2.1.2 Cytokine Assays
2.1.2.1 Outlook for Cytokine Assays
2.1.3 Genomic Germline
2.1.3.1 Outlook for Genomic Germline
2.1.4 Genomic Tumour
2.1.4.1 Outlook for Genomic Tumour
2.1.5 Tumor Microenviroment
2.1.5.1 Outlook for Tumor Micro Environment
2.1.6 Others
2.1.6.1 Outlook for Other Diagnostics

3. Industry Overview
3.1 Players in a Dynamic Market
3.1.1 Academic Research Lab
3.1.2 Diagnostic Test Developer
3.1.3 Genomic Instrumentation Supplier
3.1.3.1 Cell Separation and Viewing Instrumentation Supplier
3.1.4 Pharmaceutical/Reagent Supplier
3.1.5 Independent Testing Lab
3.1.6 Public National/regional lab
3.1.7 Hospital lab
3.1.8 Physician Lab
3.1.9 Audit Body
3.1.10 Certification Body

4. Market Trends
4.1 Factors Driving Growth
4.1.1 Outcome potential
4.1.2 Companion Diagnostics
4.1.3 Funding
4.1.4 Technology Environment
4.1.5 Target Solutions
4.2 Factors Limiting Growth
4.2.1 Complex Role of Diagnostics
4.2.2 Clinical Trials Role
4.2.3 Protocols
4.3 Diagnostic Technology Development
4.3.1 Combinations - Issues and Complexity
4.3.2 Shifting Role of Diagnostics
4.3.3 Multiplexing and Foundation One
4.3.4 The Disruption Dynamic
4.3.5 The Race for Biomarkers
4.3.6 The Next Five Years

5. Cancer Immunotherapy Recent Developments
5.1 Recent Developments - Importance and How to Use This Section
5.1.1 Importance of These Developments
5.1.2 How to Use This Section

  • ArcherDx partners with AstraZeneca for Immuno-Oncology
  • Germline Results Guides Precision Therapy
  • Agilent PD-L1 Assay Gets FDA Approval
  • Bayer, OrigiMed Form Companion Diagnostic Development Alliance
  • Bio-Me to Develop Microbiome Biomarker Test for Cancer Immunotherapy
  • SkylineDx, BioInvent Collaborate to Characterize Predictive Immunological
  • Signatures
  • Biocare Medical Launches 7 Novel IVD Antibodies
  • Oncocyte to Acquire Insight Genetics for $12M
  • Novigenix and BioLizard to develop NGS Based Diagnostic Algorithm
  • Biodesix and Immodulon Collaborate for Pancreatic Cancer Treatment
  • Generex to Merge with NuGenerex Immuno-Oncology
  • Cellgen Diagnostics and Genomic Testing Cooperative Partner to Develop
  • Companion Diagnostics for Cancer Therapies
  • Hematogenix Launches FDA Approved Immuno-oncology Test for Triple-Negative
  • Breast Cancer
  • Icon Acquires MolecularMD
  • Guardant Health to Develop Companion Diagnostic Tests for AstraZeneca
  • Tumor Mutational Burden as Predictor of Immunotherapy Success

6. Profiles of Key Immunotherapy Companies

  • Genomics
  • Abbott Laboratories
  • Abcam
  • Adaptive Biotechnologies
  • Aethlon Medical
  • Agena Bioscience
  • Angle plc
  • Apocell
  • ARUP Laboratories
  • Beckman Coulter
  • Becton Dickinson
  • Bioarray Genetics
  • BioCartis
  • Biocept
  • Biodesix Inc
  • BioFluidica
  • BioGenex
  • bioMérieux
  • Bio-Rad
  • Bio-Techne
  • Bristol-Myers Squibb
  • Cancer Genetics
  • Caris Molecular Diagnostics
  • CellMax Life
  • Charles River Laboratories
  • Chronix Biomedical
  • Circulogene
  • Clearbridge BioMedics
  • Clinical Genomics
  • Cynvenio
  • Cytolumina Technologies Corp
  • CytoTrack
  • Dako (Agilent)
  • Diagnologix LLC
  • Epic Sciences
  • Exosome Diagnostics
  • Fluidigm Corp
  • Fluxion Biosciences
  • Foundation Medicine
  • Freenome
  • Genomic Health
  • GenomOncology
  • GRAIL
  • Guardant Health
  • HalioDx
  • Horizon Discovery
  • HTG Molecular Diagnostics
  • iCellate
  • Illumina
  • Incell Dx
  • Inivata
  • Integrated Diagnostics
  • Invivoscribe
  • Leica Biosystems
  • Luminex
  • MDx Health
  • Merck & Co., Inc
  • MIODx
  • Molecular MD
  • MRM Proteomics Inc
  • Myriad Genetics/Myriad RBM
  • Nanostring
  • Natera
  • Neogenomics
  • New Oncology
  • Oncocyte
  • Ortho Clinical Diagnostics
  • Perkin Elmer
  • Personal Genome Diagnostics
  • Pfizer
  • Promega
  • Protagen Diagnostics
  • Qiagen
  • Quanterix
  • Rarecells SAS
  • Roche Diagnostics
  • Siemens
  • Silicon Biosystems
  • SkylineDx
  • SRI International
  • Sysmex
  • Thermo Fisher
  • Trovagene
  • Vortex Biosciences

7. The Global Market for Immuno-Oncology Diagnostics
7.1 Global Market Overview by Country
7.1.1 Table - Global Market by Country
7.1.2 Chart - Global Market by Country
7.2 Global Market by Assay Type - Overview
7.2.1 Table - Global Market by Assay Type
7.2.2 Chart - Global Market by Assay Type - Base/Final Year Comparison
7.2.3 Chart - Global Market by Assay Type - Base Year
7.2.4 Chart - Global Market by Assay Type - End Year
7.2.5 Chart - Global Market by Assay Type - Share by Year
7.2.6 Chart - Global Market by Assay Type - Segments Growth

8. Global Immuno-Oncology Diagnostic Markets - By Assay Type
8.1 Checkpoint
8.1.1 Table Checkpoint - by Country
8.1.2 Chart - Checkpoint Growth
8.2 Cytokine
8.2.1 Table Cytokine - by Country
8.2.2 Chart - Cytokine Growth
8.3 Germline Genetic
8.3.1 Table Germline Genetic - by Country
8.3.2 Chart - Germline Genetic Growth
8.4 Genetic Tumor
8.4.1 Table Genetic Tumor - by Country
8.4.2 Chart - Genetic Tumor Growth
8.5 Tumor Microenvironment
8.5.1 Table Tumor Microenvironment - by Country
8.5.2 Chart - Tumor Microenvironment Growth
8.6 Other
8.6.1 Table Other - by Country
8.6.2 Chart - Other Growth

9. Appendices
9.1 FDA Cancer Drug Approvals by Year
9.2 Clinical Trials Started 2010 to 2016
9.3 Prevalence of Cancer Treatments



List of Tables


Table 1 List of Cancers by Mortality
Table 2 Lab Spending 2014 to 2024
Table 3 Overview of Innate and Adaptive Immunity
Table 4 FDA Approved Monoclonal Antibodies in Cancer treatment
Table 5 FDA Approved Companion diagnostics in Cancer treatment
Table 6 Market Players by Type
Table 7 Five Factors Driving Growth
Table 8 Three Factors Limiting Growth
Table 9 - Global Market by Region
Table 10 Global Market by Assay Type
Table 11 Checkpoint by Country
Table 12 Cytokine by Country
Table 13 Germline Genetic by Country
Table 14 Genetic Tumor by Country
Table 15 Tumor Microenvironment by Country
Table 16 Other by Country

List of Figures


Figure 1 Cancer Death Rates - USA, CDC
Figure 2 Clinical Lab Spending 2014 to 2024
Figure 3 Helper T Cell Roles
Figure 4 Antibody Diagram
Figure 5 Macrophages attack a Cancer Cell
Figure 6 The Tumour Micro Environment
Figure 7 Comparing IO Diagnostic and Traditional Testing
Figure 8 Growth rates of IO DiagnosticTechnologies
Figure 9 Global Market Density Chart
Figure 10 Global Market by Assay Type - Base vs. Final
Figure 11 Global Market by Assay Type Base Year
Figure 12 Global Market by Assay Type End Year
Figure 13 Assay Type Share by Year
Figure 14 Assay Type Segments Growth
Figure 15 Checkpoint Growth
Figure 16 Cytokine Growth
Figure 17 Germline Genetic Growth
Figure 18 Genetic Tumor Growth
Figure 19 Tumor Microenvironment Growth
Figure 20 Other Growth
Figure 21 FDA Cancer Drug Approvals by Year
Figure 22 Clinical Trials for Immunotherapy by Year
Figure 23 Pie Chart of Prevalence of Cancer Treatments